Ascendis nets $112M for PhIII growth hormone trial


Ascendis Pharma ($ASND) is aiming to raise at least $112 million (€102 million) to move its long-acting growth hormone through a late-phase trial. The offering is intended to give Ascendis the means to carry out a Phase III growth hormone deficiency study while advancing other candidates that have yet to enter the clinic.

Copenhagen, Denmark-based Ascendis is offloading more than 6 million shares for $19 a pop. That would see Ascendis net $112 million, after costs, although the total could increase if the underwriters take up an option on additional shares. Either way, Ascendis is set to add a considerable sum of money to its cash pile. Ascendis closed out June with €91 million in the bank.

The money will go toward a Phase III trial of TransCon Growth Hormone. Ascendis is set to enroll the first patient in the study by the end of the year. Over the duration of the 52-week trial, Ascendis is looking to show that its once-weekly growth hormone formulation can hold its own against Pfizer’s ($PFE) Genotropin. If its drug triggers comparable improvements in annualized height velocity, Ascendis thinks the compliance benefits of the once-weekly regimen will enable it to take market share.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Ascendis is tackling the Phase III without the support of a larger partner. As such, the Danish drug developer will need deep pockets to activate approximately 100 sites, enroll 150 patients, treat them over the course of a year and package the data up for regulators. Study completion is currently penciled in for December 2018. A clearer picture of how the trial is progressing is due to emerge when Ascendis provides an update on enrollment in the first half of next year.

If the trial is a success, it will provide Ascendis with its first commercial product and raise hopes for its pipeline of assets based on the same TransCon technology. The technology takes a drug and renders it inactive. Once administered, the formulation releases the original active molecule over time. In doing so, Ascendis thinks it can create sustained-release formulations of existing drugs. Some of the $100 million will go toward work to apply the technology to parathyroid hormone and c-type natriuretic peptide.

Ascendis also has partnerships with Genentech and Sanofi ($SNY). Genentech turned to Ascendis for help making a formulation of age-related macular edema drug Lucentis that needs administering as rarely as twice a year. And Sanofi is running preclinical tests on long-acting diabetes treatments.

Suggested Articles

Profusa's latest offering provides doctors a “broader data picture” and offers patients a more convenient way to check oxygen levels in their limbs.

Digital stethoscope company Eko has received FDA clearance for its AI algorithms to help detect asymptomatic heart conditions.

After its NASH drug failed a third midphase trial, Conatus has found its lifeline—a reverse merger with regenerative medicine player Histogen.